Surface Oncology Partners with Merck for Phase 1 Trial of anti-CD39 SRF617
Surface Oncology will contribute anti-CD39 SRF617 and Merck anti-PD-1 Keytruda in the phase 1/1b trial involving patients with solid tumors.
Cancer
Adaptimmune: iT SPEAR T Cells Successfully Produced, Fight Cancer In Vitro
Adaptimmune iT SPEAR T cells, which target antigens associated with solid tumors, can be derived from stem cells and kill cancer in vitro.
NantKwest Plans Phase 2 Trial of NK Cell Pancreatic Cancer Immunotherapy
NantKwest and ImmunityBio will initiate a phase 2 trial of NK cells and IL-15 agonist N-803 for metastatic pancreatic cancer in June 2020.
T Cell Response to Chronic Infection Found to Favor Low-Affinity TCRs
Researchers from TUM studying the T cell response to chronic infection have discovered a late dominance of low-affinity TCR clones.
Multiple Myeloma Treatment Melflufen Shows Efficacy for Refractory Cancer
Everything that you should know about the multiple myeloma treatment Melflufen and the results of the phase 2 HORIZON clinical trial.
Biocept Reports Publication Further Validating Cancer-Detecting Liquid Biopsy Platform
Biocept, Inc. (Nasdaq: BIOC) has announced a clinical research publication further validating its cancer-detecting liquid biopsy platform.
Novel Engineered Nanoparticles Enhance Targeted Immunotherapy for Solid Tumors
Novel engineered nanoparticles have the ability to selectively deliver immune checkpoint blockade (ICB) therapy to tumors, allowing for targeted immunotherapy that is more efficient and has reduced side effects.
New Insights into Tumor-Associated Monocytes and Macrophages Show Promise for the Treatment of Breast and Endometrial Cancers
The unique transcriptional profiles of tumor-associated macrophages and their progenitors, tumor-educated monocytes, have been used to develop diagnostic/prognostic gene signatures for breast and endometrial cancers and suggest potent therapeutic targets.
Therapy for Steroid-Refractory and/or Resistant GvHD Favorably Alters White Blood Cell Profile
A therapy for steroid-refractory and/or resistant GvHD may function by favorably altering a population of circulating white blood cells.
Possible Combination Treatment for Patients with Cancers not Responsive to Immune Checkpoint Inhibitors
A combination treatment involving a drug stimulating an innate immune receptor could render immune checkpoint inhibitors functional in patients with otherwise unresponsive cancers.